All In Biotech

Drug Trial Radar · NCT06314698

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

A Multicenter, Randomized, Controlled, Non-inferiority Study of Narlumosbart Compared With Denosumab in the Treatment of Bone Disease in Patients With Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 478 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

478

Planned (sponsor's estimate)

Start

Apr 1, 2024

Primary completion

Dec 31, 2024

Study completion Apr 30, 2027

Sponsor

Lead sponsor
RenJi HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shanghai JMT-Bio Inc.
First posted
Mar 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if narlumosbart is non-inferior to denosumab in the treatment of bone diseases from multiple myeloma (MM).

Conditions

  • Multiple Myeloma
  • Bone Diseases

Interventions

  • NarlumosbartDrug

    Administered by subcutaneous injection once every 4 weeks.

  • DenosumabDrug

    Administered by subcutaneous injection once every 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in urinary N-terminal telopeptide of type 1 collagen corrected for urinary creatinine (uNTx/uCr) at week 13Time frame: From baseline to week 13

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.